For 2026, the landscape of Alzheimer’s treatment has officially shifted from a “symptom management” era to a “disease-modifying” era. For years, medications only temporarily masked memory loss and confusion. Today, we are seeing the first generation of therapies that target the underlying biological causes of the disease, specifically by clearing toxic proteins from the brain.
This progress is fueled by advances in biomarkers, blood tests, and brain imaging, which enable more precise diagnoses and earlier intervention. While these newer treatments for Alzheimer's Disease are not a cure, they can slow the inevitable cognitive decline, offering families more “quality time” where patients can remain independent and engaged.
Whether you are exploring options for early-stage mild cognitive impairment or seeking support for advanced dementia, this updated guide covers the latest FDA-approved tools and the most promising treatments nearing completion in clinical trials.
How Diagnosing Alzheimer's Disease Has Changed for 2026
In the past, a diagnosis was often based solely on visible symptoms and “ruling out” other conditions. Today, the process is much more proactive and precise. Physicians now use biomarkers to see what is happening inside the brain long before significant memory loss occurs.
- Advanced Blood Tests: New, highly accurate blood tests can now detect the hallmarks of Alzheimer’s with a simple blood draw, often replacing the need for invasive spinal taps.
- Amyloid PET Scans: These specialized brain scans allow doctors to “see” the plaque buildup that drugs like Leqembi and Kisunla are designed to target.
- Earlier Intervention: Because of these tools, many people are being diagnosed at the Mild Cognitive Impairment (MCI) stage, which is the “Goldilocks zone” where new disease-modifying treatments are most effective.
1. Disease-Modifying Therapies for Alzheimer's Disease: The “New” Standard
Unlike older drugs that only manage symptoms, these therapies are designed to slow the progression of Alzheimer's Disease by removing amyloid plaques from the brain. They are primarily for people in the early stages (Mild Cognitive Impairment or Mild Dementia).
Leqembi (lecanemab-irmb)
Originally approved as a biweekly IV infusion, the drug received FDA approval for a subcutaneous weekly formulation in August 2025, which may enable more convenient at-home administration.
Kisunla (donanemab-azbt)
Approved in July 2024, this monthly IV infusion allows some patients to stop treatment once brain scans show their plaques have been sufficiently cleared.
Aduhelm (aducanumab)
Although it was the first in this class, the manufacturer voluntarily withdrew it from the market in 2024 due to business decisions.
Safety Note: These drugs require regular MRI monitoring to check for ARIA (Amyloid-Related Imaging Abnormalities), which can include temporary brain swelling or small bleeds.
2. Symptomatic Medications for Treating Alzheimer's Disease (The Core Support)
These medications do not cure the disease, but they help brain cells communicate more effectively to support thinking and memory.
Cholinesterase Inhibitors (for Mild to Moderate stages of Alzheimer's Disease)
- Aricept (donepezil): Approved for all stages.
- Exelon (rivastigmine): Available as a pill or a skin patch.
- Razadyne (galantamine): Used for mild-to-moderate dementia.
- Zunveyl (benzgalantamine): A newer option approved for mild-to-moderate dementia.
Glutamate Regulators (for Moderate to Severe stages of Alzheimer's Disease)
- Namenda (memantine): Helps regulate brain chemical activity involved in information processing.
Combination Therapy for Treating Alzheimer's Disease
- Namzaric: A single capsule combining donepezil and memantine.
3. Alzheimer's Medications for Treating Behavioral & Sleep Symptoms
Managing quality of life is just as critical as managing one's memory.
Belsomra (suvorexant)
FDA-approved to treat insomnia in people with mild to moderate Alzheimer’s.
Rexulti (brexpiprazole)
Specifically approved to treat agitation associated with Alzheimer’s dementia.
Upcoming – AXS-05
An oral medication for Alzheimer’s agitation is currently under “Priority Review” by the FDA, with a decision expected by April 30, 2026.
VIDEO: 2026 Update – New Alzheimer's Drugs Signal a Turning Point
Pro Tip: Beware of Scams When it Comes to Alzheimer's Therapy!
It’s important to know that there aren’t any current medications that can cure Alzheimer’s yet. Beware of untested or unproven “cures” or claims when it comes to Alzheimer's Disease.
Check with your loved one's doctor before trying any pills, supplements, or other products that claim to improve memory or cure brain disorders. These so-called treatments might be unsafe, a waste of money, or both. Even worse, they might interfere with real medical treatments.
Table 1: Summary of Approved Medications for Alzheimer's Disease
This table summarizes the medications currently available. It includes “disease-modifying” therapies that slow the progression of the disease, as well as symptomatic treatments that help manage memory, thinking, and common behavioral challenges like agitation and insomnia.
| Medication Class | Drug Name | Approved For | Administration |
|---|---|---|---|
| Disease-Modifying | Leqembi | Early Stage | IV Infusion or Weekly Subcutaneous Injection |
| Disease-Modifying | Kisunla | Early Stage | Monthly IV Infusion |
| Cholinesterase Inhibitor | Aricept | All Stages | Oral Pill |
| Cholinesterase Inhibitor | Zunveyl | Mild to Moderate | Oral Pill |
| Glutamate Regulator | Namenda | Moderate to Severe | Oral Pill |
| Agitation Treatment | Rexulti | Agitation in AD | Oral Pill |
| Sleep Aid | Belsomra | Insomnia in AD | Oral Pill |
Table 2: Promising Alzheimer's Disease Medications in Clinical Trials
The following treatments are currently in Phase 3 clinical trials, the final stage of testing before the FDA decides on approval. These medications are particularly exciting because many offer new ways of taking the drug (like a once-daily pill) or target different biological pathways than existing therapies.
| Drug Name | Purpose | Why it’s Promising |
|---|---|---|
| Remternetug | Amyloid Clearance | A “successor” to Kisunla, being tested as a more convenient subcutaneous injection; Phase 3 data expected March 2026. |
| AR1001 (Mirodenafil) | Oral Disease Modifier | A once-daily oral pill for early Alzheimer's that aims to protect neurons; final results are projected for 2026/2027. |
| Buntanetap | Triple-Pathway Target | Designed to stop the production of three toxic proteins (amyloid, tau, and alpha-synuclein) simultaneously. |
| Semaglutide | Anti-Inflammatory | The active ingredient in Wegovy/Ozempic is being studied for its potential to reduce brain inflammation in early Alzheimer’s. |
Table 3: Safety Monitoring for Disease-Modifying Therapies
The newest class of treatments, such as Leqembi and Kisunla, requires vigilant monitoring for a condition known as ARIA (Amyloid-Related Imaging Abnormalities). This table outlines what patients and caregivers should expect regarding safety protocols.
| Monitoring Requirement | Purpose | Frequency |
|---|---|---|
| Periodic MRI Scans | To detect ARIA (brain swelling or small bleeds), which can often be asymptomatic. | Required before starting and at specific intervals during the first several months of treatment. |
| Genetic Testing (APOE4) | To assess the risk of developing ARIA; those with two copies of the APOE4 gene are at higher risk. | Recommended once before beginning therapy. |
| Neurological Assessments | To monitor for clinical signs of side effects like headache, confusion, or dizziness. | Conducted during routine check-ups and infusion appointments. |
Understanding Medicare Coverage and Costs
While the FDA's approval of disease-modifying drugs is an exciting breakthrough, accessing them can be financially complex. Drugs like Leqembi and Kisunla come with high annual price tags.
Currently, Traditional Medicare will cover these medications for eligible patients in the early stages of the disease, provided the prescribing physician participates in a qualifying registry to track the drug's real-world effectiveness.
However, caregivers must also account for the secondary costs associated with these treatments, such as the required bi-weekly or monthly facility infusion fees, routine MRI monitoring for Amyloid-related imaging abnormalities (ARIA), and the initial amyloid PET scans required for diagnosis, which may carry separate out-of-pocket copays.
Questions to Ask Your Doctor About Alzheimer's Medications
- Is my loved one at the right stage for a disease-modifying therapy like Leqembi or Kisunla? These are generally reserved for early-stage or mild cognitive impairment.
- What are the specific risks of ARIA for them, and how will they be monitored? Ask about the frequency of required MRI scans.
- Does the facility offer at-home options? Inquire whether the new subcutaneous (under-the-skin) version of Leqembi is available for maintenance.
- For symptomatic drugs like Aricept or Namenda, how will we know if they are working? Since these drugs manage symptoms rather than the disease itself, ask what benchmarks the doctor uses to track effectiveness.
- What is the long-term plan for discontinuing treatment? It is important to have a plan for when medications may no longer be beneficial as the disease progresses.
Questions for Your Doctor About Alzheimer's Treatments (printable format)
📋 Questions to Ask Your Doctor Checklist
- Is my loved one at the right stage for a disease-modifying therapy? (Usually early-stage/MCI).
- What are the specific ARIA risks for their profile? (Ask about genetic testing for APOE4).
- Are at-home subcutaneous maintenance injections available? (Available for Leqembi as of late 2025).
- What benchmarks will we use to track effectiveness? (Define what success looks like for symptomatic drugs).
- What is the long-term plan for discontinuing treatment? (Vital for advanced stages).
Frequently Asked Questions About Alzheimer's Medications
Do the newest Alzheimer's medications cure the disease?
No, there is currently no cure for Alzheimer's disease. However, the newest class of FDA-approved disease-modifying drugs, such as Leqembi and Kisunla, are proven to remove amyloid plaques from the brain, which can significantly slow down cognitive decline when administered in the early stages of the disease.
What is the difference between Aricept and Leqembi?
Aricept (donepezil) is a symptomatic medication; it temporarily helps brain cells communicate better to manage memory loss but does not stop the disease from progressing. Leqembi is a disease-modifying therapy that targets the underlying biology of Alzheimer's by clearing toxic proteins to slow the actual progression of the disease.
Can someone in the late stages of Alzheimer's take the new IV drugs?
No. Disease-modifying therapies like Kisunla and Leqembi are strictly approved for individuals with Mild Cognitive Impairment (MCI) or early-stage mild dementia. They are not effective or approved for patients in the moderate or severe stages of the disease.
Conclusion: Modern Alzheimer's Treatments Provide Hope
Navigating an Alzheimer's diagnosis is exhausting, and keeping up with the rapid changes in FDA-approved treatments adds another layer of stress to your caregiving plate. While the newest disease-modifying therapies offer unprecedented hope for slowing cognitive decline and preserving independence, they are not a silver bullet.
Every medication comes with a unique balance of potential benefits, financial costs, and safety risks. Use this guide to confidently advocate for your loved one. Bring the checklist above to your next neurology appointment, ask direct questions about side effects and Medicare coverage, and partner with your medical team to build a realistic care plan that prioritizes your family member's quality of life.
- 3 Stages of Dementia: What to Expect as the Disease Progresses
- Untreated Pain in Dementia: Signs, Causes, and Treatments
- 5 Types of Medications for Alzheimer’s Behavior: Effectiveness, Benefits, and Risks
About the Author
Connie is the founder of DailyCaring.com and was a hands-on caregiver for her grandmother for 20 years. (Grandma made it to 101 years old!) She knows how challenging, overwhelming, and all-consuming caring for an older adult can be. She also understands the importance of support, especially in the form of practical solutions, valuable resources, and self-care tips.
So appreciative of your web site ! We are entering into the latter stage of dementia and difficulty in the administration of medications. I will consult with her Doctor to see which of them we can consider cease to use.
Again, my thanks
Just an Old Soldier
So glad our articles are useful! It’s a great idea to ask the doctor to do a full medication review, including over-the-counter and supplements, in case any can be safely discontinued.
In case it helps, we also have an article with tips on how to get someone with dementia to take their medication — 11 Ways to Get Someone with Dementia to Take Medication https://dailycaring.com/11-ways-to-get-someone-with-dementia-to-take-medication/